Deleted in Colorectal Cancer
|, DCC netrin 1 receptor, CRC18, CRCR1, IGDCC1, MRMV1, NTN1R1, HGPPS2|
Deleted in Colorectal Carcinoma, also known as DCC, is a protein which in humans is encoded by the DCC gene. DCC has long been implicated in colorectal cancer. While the official, full name of this gene is Deleted in Colorectal Carcinoma, it is almost universally called Deleted in Colorectal Cancer. The protein product of DCC is a single transmembrane receptor also known as DCC, and it has the same interchangeable name.
Since it was first discovered in a colorectal cancer study in 1990, DCC has been the focus of a significant amount of research. DCC held a controversial place as a tumour suppressor gene for many years, and is well known as an axon guidance receptor that responds to netrin-1.
More recently DCC has been characterized as a dependence receptor, and many hypotheses have been put forward that have revived interest in DCC's candidacy as a tumour suppressor gene, as it may be a ligand-dependent suppressor that is frequently epigenetically silenced.
- 1 Background
- 2 Structure
- 3 DCC as a dependence receptor
- 4 Developmental and neurological roles
- 5 Role in cancer
- 6 Pharmacology
- 7 Interactions
- 8 History
- 9 References
- 10 Further reading
- 11 External links
Early studies of colorectal tumours found that allelic deletions of segments of chromosome 18q occur in a very high percentage of colorectal cancers. DCC was initially cloned out of the region and put forth as a putative tumour suppressor gene, though nothing was known about its function at the time. The DCC gene was examined for the genetic changes found with most other tumour suppressor genes, but it was found to have a comparatively low frequency of somatic mutation. Several years later DCC was shown to encode a transmembrane receptor protein that mediated the effects of netrin-1 on axon outgrowth.
Soon after the protein product was confirmed, DCC knockout mice were created. As DCC−/− mutations are rapidly fatal due to a lack of nervous system development, DCC+/− mice were assessed for increased tumour development over two years, and no increase in tumour predisposition was detected.
The discovery of a specific function for DCC that seemed to have little to do with cell cycle control, the low somatic mutation rate and the absence of cancer predisposition in DCC heterozygotes were fairly discouraging evidence for DCC's putative tumour suppressor status. This caused focus to shift to DCC's role in axon guidance for a time, until one study implicated DCC in regulation of cell death. As the 18q chromosomal deletions were never resolved to be related solely to another gene, DCC was rapidly reaccepted as a candidate. Recent research into the mechanisms of DCC signaling and in-vitro studies of DCC modifications have solidified DCC's tumour suppressor position, and have begun to integrate DCCs divergent functions as both an axon guidance molecule and a tumour suppressor into a single concept.
The DCC gene is located at 18q21.3, and has a total of 57 possible exons and 43 possible introns. This theoretically results in 13 correctly sliced, putatively good proteins. The typical DCC protein has one signal peptide motif and eleven domains, including multiple immunoglobulin-like domains, a transmembrane domain, and several fibronectin type 3 domains.
DCC has extracellular binding sites for both netrin-1 and heparin. Heparin sulphate is believed to also be present during neural growth as a type of co-factor for axon guidance. Intracellularly, DCC has been shown to have a caspase-3 proteolysis site at Asp 1290.
DCC and neogenin, two of the netrin-1 receptors, have recently been shown to have sites for tyrosine phosphorylation (at Y1420 on DCC) and are likely interacting with Src family kinases in regulating responses to netrin-1.
DCC as a dependence receptor
Historically, cellular receptors have been thought to be activated when bound to their ligand, and are relatively inactive when no ligand is present. A number of receptors have been found that do not fit into this conceptual mould, and DCC is one of them. These receptors are active both with ligand bound and unbound, but the signals transmitted are different when the receptors are ligand bound. Collectively, this type of receptor is known as a dependence receptor because the unbound pathway is usually apoptotic, meaning that cell survival depends on ligand presence. Other receptors also show this functional profile, including p75NTR, the androgen receptor, RET, several integrins and Patched.
While not the first dependence receptor pair discovered, DCC and netrin-1 are an often quoted example of a dependence receptor system. When DCC is present on the membrane and bound to netrin-1, signals are conveyed that can lead to proliferation and cell migration. In the absence of netrin-1, DCC signaling has been shown to induce apoptosis. Only in the absence of DCC is there an absence of downstream signaling. There are therefore three possible signaling states for dependence receptors: on (ligand-bound, migration and proliferation), off (ligand-unbound, apoptosis inducing) and absent (lack of signal).
Developmental and neurological roles
DCC's role in commissural axon outgrowth is perhaps its best characterized. In the developing spinal cord, commissural neurons located dorsally extend axons ventrally using a mechanism dependent on a ventral midline structure, the floor plate. A gradient of netrin-1 is produced from the floor plate, which allows orientation of the extending axons, aiding the development of the dorsal-ventral axis of the brain and spinal column. A variety of receptors are present on the axon surface which either repel or attract axons to the midline. When membrane DCC is stimulated by netrin-1, it promotes axon progression towards the midline.
There are several other molecules also involved in the guidance of axons to and across the midline. The slit proteins have repulsive functions, as opposed to netrins, and are mediated by the transmembrane protein Robo. Axonal growth cones that are attracted to the midline by netrin/DCC signaling eventually cross the floor plate. When this occurs they lose responsiveness to netrin and become repulsed by slit/Robo signaling. This is accomplished by the formation of a DCC-Robo complex, which inhibits attractive netrin/DCC signals while allowing slit/Robo signals. Netrin also has other receptors, the UNC-5 family. The UNC5 receptors have repellant migratory responses to netrin binding, and have similar effects to the slit/Robo system.
The intracellular signaling responses to netrin-1 are not yet well understood, even in neurobiology studies. Several phosphorylation events have been established, as have the involvement of several src family kinases and small GTPases, but the sequence of events has not yet been determined. DCC is also required to be recruited to lipid rafts for axon outgrowth and apoptotic signaling.
DCC is developmentally regulated, being present in most fetal tissues of the body at higher levels than what is found in adult tissues. DCC and netrin have been found to be specifically involved in the secondary migration of neural crest cells into the pancreas and developing gut structures, and may prove to be vital to other areas during fetal growth.
Role in cancer
One of the most frequent genetic abnormalities that occur in advanced colorectal cancer is loss of heterozygosity (LOH) of DCC in region 18q21.
DCC in a receptor for netrin-1 and is currently believed by some to be a conditional tumour suppressor gene, meaning that it normally prevents cell growth when in the absence of netrin-1. DCC elimination is not believed to be a key genetic change in tumour formation, but one of many alterations that can promote existing tumour growth. DCC's possible role in migration of cancerous cells is in the process of being characterized.
While recent results make it fairly likely that DCC is involved in the biology of several cancers, the extent of its involvement and the details of how it works are still being studied.
Normal function in tumour suppression and apoptosis
When not bound to netrin-1, an intracellular domain of DCC is cleaved by a caspase, and induces apoptosis in a caspase-9-dependent pathway. This domain does not correspond to a known caspase recruitment motif or death sequence domain, but is required to initiate apoptosis. It has been theorized that the domain acts as a scaffold to recruit and activate caspase-9 and caspase-3. This DCC apoptosis pathway is not dependent on either the mitochondrial apoptosis pathway or the death receptor/caspase-8 pathway. In the absence of ligand, DCC interacts with caspase-9 (likely via an unidentified adaptor protein) and promotes the assembly of a caspase-activating complex. This causes the activation of caspase-3 through caspase-9, and initiates apoptosis without the formation of an apoptosome or cytochrome c release. This implies that DCC regulates a novel pathway for caspase activation, and that it is one that is apoptosome-independent.
To put this into a biological systems context, some physiology is required. In the gastrointestinal tract, epithelial cells proliferate and die rapidly. The division of these cells occurs at the base of villi, and cells are pushed upwards by subsequent divisions to the tip where they enter apoptosis and shed off into the lumen. Netrin-1 is produced in the base of the villi, so a gradient of netrin is present that is weakest at the tip. In normal physiology, the presence of netrin-1 inhibits DCC-mediated cell death until the epithelial cell reaches the tip of the villus, where the now unbound DCC causes the cell to enter apoptosis. In a cancer state, the absence of DCC prevents the gradient from having an effect on the cell, making it more likely to continue to survive.
DCC's role as a tumour suppressor is tied to its dependence receptor characteristics. DCC induces cell death on epithelial cells when no netrin-1 is bound. Besides from loss of heterozygosity of DCC, this mechanism of apoptosis can also be avoided in malignant processes by overexpression of netrin-1.
As an oncogene
DCC can be considered a conditional tumour suppressor gene as well as a conditional oncogene. When DCC is present and not activated by netrin it is proapoptotic, and represses tumour formation. When DCC is present and netrin-activated it promotes cell survival, acting as an oncoprotein. Netrin-activated DCC is known to activate the CDC42-RAC1 and MAPK1/3 pathways, both of which are activated in cancer and promote tumour development.
Mechanism of deletion
It was originally believed that there were two major pathways in colorectal cancer formation. The first was a chromosomal instability pathway thought to be responsible for the adenoma to carcinoma progression, which was characterized by loss of heterozygosity (LOH) on chromosome 5q, 17p and 18q. The second pathway was believed to be the microsatellite instability pathway, which is characterized by increases or decreases in the number of tandem repeats of simple DNA sequences. This type of instability is associated with some specific mutations, including genes involved with DNA mismatch repair and surprisingly, transforming growth factor-beta. More recently, those in the field of colorectal cancer have acknowledged that cancer formation is far more complex, but cancer related genes still tend to be categorized as chromosomal or microsatellite instability genes.
DCC would fall into the chromosomal instability category. The chromosomal region of 18q has shown consistent LOH for nearly twenty years. Approximately 70% of primary colorectal cancers display LOH in this region, and the percentage increases when comparing early to advanced cancers. This increase in DCC loss in advanced cancer may indicate that DCC loss is more important to tumour progression than tumour formation. However, region 18q is not the location of DCC alone, and many studies are in conflict when reporting whether 18q LOH is attributable to DCC or other tumour suppressor candidates in the neighbouring areas. Many reviews refuse to comment on DCC due to its history of conflicting information, stating that more study is required.
Chromosome 18 LOH tends to occur in clusters. One major cluster is at 18q21, which agrees with the location of DCC. This cluster includes the marker D18S51, and is flanked by the D18S1109 and D18S68 loci. This segment spans 7.64cM, which is a relatively large section of DNA that could easily encompass more than one tumour suppressor gene.
A significant difference between DCC expression and 18q21 LOH was detected in 1997. Studies found that more tumours had reduced DCC expression than could be explained by LOH or MSI, indicating that another mechanism was at work. This observation was likely explained when epigenetic analysis was performed.
Loss of DCC in colorectal cancer primarily occurs via chromosomal instability, with only a small percent having epigenetic silencing involved.
Epigenetic silencing of DCC by promoter hypermethylation has shown to be a significant factor in other cancer types. In head and neck squamous cell carcinoma, 77.3% of tumour samples presented DCC promoter hypermethylation versus 0.8% in non-cancerous saliva samples. Similar results have been seen in breast cancer, acute lymphoblastic leukemia, and several others.
Use in pharmacogenetics
DCC has found to be a useful prognostic marker for late stage colorectal carcinoma in some studies, but unhelpful in others. Currently the American Society of Clinical Oncology does not recommend using DCC as a marker due to insufficient classification data.
A recent review of over two dozen 18q LOH-survival studies concluded that there was a significant amount of inconsistency between the data sets. They concluded that loss of 18q remains a marker for poor prognosis, and that DCC status has the potential to define a group of patients who may benefit from specific treatment regimes.
The increase in loss of heterozygosity percentages of chromosome 18q21 have long suggested that DCC may be involved in the progression of benign adenomas to malignant carcinomas. DCC has recently been found to suppress metastasis in an experimental environment, but a mechanism for this has not yet been proposed.
At this junction, DCC is not a pharmaceutical target. As DCC is not overexpressed in cancer and is present throughout the body, so it is not considered a good target for most types of cancer drugs.
DCC is expressed at very low levels through most of the body but at higher levels in many areas of the brain, particularly in dopamine neurons. Recently it has been shown that a sensitizing treatment regimen of amphetamines causes markedly increased levels of DCC and UNC-5 expression on neuron cell bodies. This may indicate that netrin-1 receptors are involved in the lasting effects of exposure to stimulant drugs like amphetamine, and may have some therapeutic value in the field of drug tolerance.
Deleted in Colorectal Cancer has been shown to interact with:
DCC's biological role in cancer has had a long, controversial history. Although DCC has been studied for many years, a significant amount of the data collected is contradictory and much of the focus has been on getting clear picture of the basics.
When the genetic abnormalities that occur in advanced colorectal cancer were first identified, one of the most frequent events was found to be loss of heterozygosity (LOH) of region 18q21. One of the first genes sequenced in this region was DCC, and it was subsequently analyzed for tumour suppressor activity. However, the lack of somatic DCC mutations made it seem likely that the nearby SMAD2 and SMAD4 genes were the reason for 18q21 LOH. The fact that DCC heterozygotes had no increased rates of cancer, even when crossed with mice carrying Apc mutations, solidified this viewpoint. The finding that DCC was a receptor for netrin-1 involved in axon guidance initially moved research away from DCC in cancer. It was later realized that DCC may be involved in directing cell motility, which has direct implications for metastatic cancer.
The first direct evidence for DCC as a tumour suppressor gene was published in 1995. Researchers found that addition of DCC to an immortalized cell line suppressed tumorigenicity rather definitively. However no mechanism for this suppression was obvious, and it took several years to propose one.
Nearly ten years after DCC was discovered, studies were published that showed that DCC was involved in apoptosis. Instead of studying loss of DCC as was commonly done, the authors looked at human embryonic kidney cells transfected with DCC. They found an increase in apoptosis that corresponded to DCC expression, which was completely eliminated when netrin-1 was co-transfected or simply added to the media.
When it was understood that DCC apoptosis may also be overcome by netrin-1 overexpression, colorectal cancers were assessed for netrin-1 overexpression, and a small but significant percent of these cancers were found to vastly overexpress the molecule.
- GRCh38: Ensembl release 89: ENSG00000187323 - Ensembl, May 2017
- GRCm38: Ensembl release 89: ENSMUSG00000060534 - Ensembl, May 2017
- "Human PubMed Reference:".
- "Mouse PubMed Reference:".
- NCBI Website for DCC
- Fearon ER, Cho KR, Nigro JM, Kern SE, Simons JW, Ruppert JM, Hamilton SR, Preisinger AC, Thomas G, Kinzler KW (January 1990). "Identification of a chromosome 18q gene that is altered in colorectal cancers". Science. 247 (4938): 49–56. doi:10.1126/science.2294591. PMID 2294591.
- Bernet A, Mehlen P (April 2007). "Dependence receptors: when apoptosis controls tumor progression". Bull Cancer. 94 (4): E12–7. PMID 17449433.
- Arakawa H (December 2004). "Netrin-1 and its receptors in tumorigenesis". Nature Reviews Cancer. 4 (12): 978–87. doi:10.1038/nrc1504. PMID 15573119.
- Keino-Masu K, Masu M, Hinck L, Leonardo ED, Chan SS, Culotti JG, Tessier-Lavigne M (October 1996). "Deleted in Colorectal Cancer (DCC) encodes a netrin receptor". Cell. 87 (2): 175–85. doi:10.1016/S0092-8674(00)81336-7. PMID 8861902.
- Fazeli A, Dickinson SL, Hermiston ML, Tighe RV, Steen RG, Small CG, Stoeckli ET, Keino-Masu K, Masu M, Rayburn H, Simons J, Bronson RT, Gordon JI, Tessier-Lavigne M, Weinberg RA (April 1997). "Phenotype of mice lacking functional Deleted in colorectal cancer (Dcc) gene". Nature. 386 (6627): 796–804. doi:10.1038/386796a0. PMID 9126737.
- Mehlen P, Rabizadeh S, Snipas SJ, Assa-Munt N, Salvesen GS, Bredesen DE (October 1998). "The DCC gene product induces apoptosis by a mechanism requiring receptor proteolysis". Nature. 395 (6704): 801–4. doi:10.1038/27441. PMID 9796814.
- AceView: Homo sapiens complex locus DCC, encoding deleted in colorectal carcinoma
Thierry-Mieg D, Thierry-Mieg J (2006). "AceView: a comprehensive cDNA-supported gene and transcripts annotation". Genome Biol. 7 (Suppl 1): S12.1–14. doi:10.1186/gb-2006-7-s1-s12. PMC . PMID 16925834.
- Human Protein Reference Database: DCC
- Bennett KL, Bradshaw J, Youngman T, Rodgers J, Greenfield B, Aruffo A, Linsley PS (October 1997). "Deleted in colorectal carcinoma (DCC) binds heparin via its fifth fibronectin type III domain". J Biol Chem. 272 (43): 26940–6. doi:10.1074/jbc.272.43.26940. PMID 9341129.
- Matsumoto Y, Irie F, Inatani M, Tessier-Lavigne M, Yamaguchi Y (April 2007). "Netrin-1/DCC signaling in commissural axon guidance requires cell-autonomous expression of heparan sulfate". J. Neurosci. 27 (16): 4342–50. doi:10.1523/JNEUROSCI.0700-07.2007. PMID 17442818.
- Ren XR, Hong Y, Feng Z, Yang HM, Mei L, Xiong WC (2008). "Tyrosine phosphorylation of netrin receptors in netrin-1 signaling". Neurosignals. 16 (2-3): 235–45. doi:10.1159/000111566. PMID 18253061.
- Mehlen P, Bredesen DE (January 2004). "The dependence receptor hypothesis". Apoptosis. 9 (1): 37–49. doi:10.1023/B:APPT.0000012120.66221.b2. PMID 14739597.
- Grady WM (December 2007). "Making the case for DCC and UNC5C as tumor-suppressor genes in the colon". Gastroenterology. 133 (6): 2045–9. doi:10.1053/j.gastro.2007.10.034. PMID 18054576.
- Stein E, Tessier-Lavigne M (March 2001). "Hierarchical organization of guidance receptors: silencing of netrin attraction by slit through a Robo/DCC receptor complex". Science. 291 (5510): 1928–38. doi:10.1126/science.1058445. PMID 11239147.
- Hérincs Z, Corset V, Cahuzac N, Furne C, Castellani V, Hueber AO, Mehlen P (April 2005). "DCC association with lipid rafts is required for netrin-1-mediated axon guidance". J Cell Sci. 118 (Pt 8): 1687–92. doi:10.1242/jcs.02296. PMID 15811950.
- Furne C, Corset V, Hérincs Z, Cahuzac N, Hueber AO, Mehlen P (March 2006). "The dependence receptor DCC requires lipid raft localization for cell death signaling". Proc Natl Acad Sci USA. 103 (11): 4128–33. doi:10.1073/pnas.0507864103. PMC . PMID 16537496.
- Jiang Y, Liu MT, Gershon MD (June 2003). "Netrins and DCC in the guidance of migrating neural crest-derived cells in the developing bowel and pancreas". Dev. Biol. 258 (2): 364–84. doi:10.1016/S0012-1606(03)00136-2. PMID 12798294.
- Forcet C, Ye X, Granger L, Corset V, Shin H, Bredesen DE, Mehlen P (March 2001). "The dependence receptor DCC (deleted in colorectal cancer) defines an alternative mechanism for caspase activation". Proc Natl Acad Sci USA. 98 (6): 3416–21. doi:10.1073/pnas.051378298. PMC . PMID 11248093.
- Takayama T, Miyanishi K, Hayashi T, Sato Y, Niitsu Y (March 2006). "Colorectal cancer: genetics of development and metastasis". J Gastroenterol. 41 (3): 185–92. doi:10.1007/s00535-006-1801-6. PMID 16699851.
- Yin Z, Babaian RJ, Troncoso P, Strom SS, Spitz MR, Caudell JJ, Stein JD, Kagan J (April 2001). "Limiting the location of putative human prostate cancer tumor suppressor genes on chromosome 18q". Oncogene. 20 (18): 2273–80. doi:10.1038/sj.onc.1204310. PMID 11402322.
- Kong XT, Choi SH, Inoue A, Xu F, Chen T, Takita J, Yokota J, Bessho F, Yanagisawa M, Hanada R, Yamamoto K, Hayashi Y (1 September 1997). "Expression and mutational analysis of the DCC, DPC4, and MADR2/JV18-1 genes in neuroblastoma". Cancer Res. 57 (17): 3772–8. PMID 9288786.
- Carvalho AL, Chuang A, Jiang WW, Lee J, Begum S, Poeta L, Zhao M, Jerónimo C, Henrique R, Nayak CS, Park HL, Brait MR, Liu C, Zhou S, Koch W, Fazio VM, Ratovitski E, Trink B, Westra W, Sidransky D, Moon CS, Califano JA (October 2006). "Deleted in colorectal cancer is a putative conditional tumor-suppressor gene inactivated by promoter hypermethylation in head and neck squamous cell carcinoma". Cancer Res. 66 (19): 9401–7. doi:10.1158/0008-5472.CAN-06-1073. PMID 17018594.
- Popat S, Houlston RS (September 2005). "A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis". Eur J Cancer. 41 (14): 2060–70. doi:10.1016/j.ejca.2005.04.039. PMID 16125380.
- Miyaki M, Seki M, Okamoto M, Yamanaka A, Maeda Y, Tanaka K, Kikuchi R, Iwama T, Ikeuchi T, Tonomura A (15 November 1990). "Genetic changes and histopathological types in colorectal tumors from patients with familial adenomatous polyposis". Cancer Res. 50 (22): 7166–73. PMID 1977514.
- Rodrigues S, De Wever O, Bruyneel E, Rooney RJ, Gespach C (August 2007). "Opposing roles of netrin-1 and the dependence receptor DCC in cancer cell invasion, tumor growth and metastasis". Oncogene. 26 (38): 5615–25. doi:10.1038/sj.onc.1210347. PMID 17334389.
- Yetnikoff L, Labelle-Dumais C, Flores C (December 2007). "Regulation of netrin-1 receptors by amphetamine in the adult brain". Neuroscience. 150 (4): 764–73. doi:10.1016/j.neuroscience.2007.09.069. PMC . PMID 17996376.
- Liu J, Yao F, Wu R, Morgan M, Thorburn A, Finley RL, Chen YQ (Jul 2002). "Mediation of the DCC apoptotic signal by DIP13 alpha". J. Biol. Chem. 277 (29): 26281–5. doi:10.1074/jbc.M204679200. PMID 12011067.
- Wafa LA, Cheng H, Rao MA, Nelson CC, Cox M, Hirst M, Sadowski I, Rennie PS (Oct 2003). "Isolation and identification of L-dopa decarboxylase as a protein that binds to and enhances transcriptional activity of the androgen receptor using the repressed transactivator yeast two-hybrid system". Biochem. J. 375 (Pt 2): 373–83. doi:10.1042/BJ20030689. PMC . PMID 12864730.
- Forcet C, Ye X, Granger L, Corset V, Shin H, Bredesen DE, Mehlen P (Mar 2001). "The dependence receptor DCC (deleted in colorectal cancer) defines an alternative mechanism for caspase activation". Proc. Natl. Acad. Sci. U.S.A. 98 (6): 3416–21. doi:10.1073/pnas.051378298. PMC . PMID 11248093.
- Ugai H, Li HO, Komatsu M, Tsutsui H, Song J, Shiga T, Fearon E, Murata T, Yokoyama KK (Sep 2001). "Interaction of Myc-associated zinc finger protein with DCC, the product of a tumor-suppressor gene, during the neural differentiation of P19 EC cells". Biochem. Biophys. Res. Commun. 286 (5): 1087–97. doi:10.1006/bbrc.2001.5469. PMID 11527412.
- Geisbrecht BV, Dowd KA, Barfield RW, Longo PA, Leahy DJ (Aug 2003). "Netrin binds discrete subdomains of DCC and UNC5 and mediates interactions between DCC and heparin". J. Biol. Chem. 278 (35): 32561–8. doi:10.1074/jbc.M302943200. PMID 12810718.
- Meyerhardt JA, Caca K, Eckstrand BC, Hu G, Lengauer C, Banavali S, Look AT, Fearon ER (Jan 1999). "Netrin-1: interaction with deleted in colorectal cancer (DCC) and alterations in brain tumors and neuroblastomas". Cell Growth Differ. 10 (1): 35–42. PMID 9950216.
- Ren XR, Ming GL, Xie Y, Hong Y, Sun DM, Zhao ZQ, Feng Z, Wang Q, Shim S, Chen ZF, Song HJ, Mei L, Xiong WC (Nov 2004). "Focal adhesion kinase in netrin-1 signaling". Nat. Neurosci. 7 (11): 1204–12. doi:10.1038/nn1330. PMID 15494733.
- Klingelhutz AJ, Hedrick L, Cho KR, McDougall JK (April 1995). "The DCC gene suppresses the malignant phenotype of transformed human epithelial cells". Oncogene. 10 (8): 1581–6. PMID 7731713.
- Friess H, Berberat P, Schilling M, Kunz J, Korc M, Büchler MW (January 1996). "Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors". J Mol Med. 74 (1): 35–42. doi:10.1007/BF00202070. PMID 8834768.
- Arakawa H (2005). "Netrin-1 and its receptors in tumorigenesis". Nature Reviews Cancer. 4 (12): 978–87. doi:10.1038/nrc1504. PMID 15573119.
- Nigro JM, Cho KR, Fearon ER, Kern SE, Ruppert JM, Oliner JD, Kinzler KW, Vogelstein B (1991). "Scrambled exons". Cell. 64 (3): 607–13. doi:10.1016/0092-8674(91)90244-S. PMID 1991322.
- Fearon ER, Cho KR, Nigro JM, Kern SE, Simons JW, Ruppert JM, Hamilton SR, Preisinger AC, Thomas G, Kinzler KW (1990). "Identification of a chromosome 18q gene that is altered in colorectal cancers". Science. 247 (4938): 49–56. doi:10.1126/science.2294591. PMID 2294591.
- Fearon ER, Ekstrand BC, Hu G, Pierceall WE, Reale MA, Bigner SH (1995). "Studies of the deleted in colorectal cancer gene in normal and neoplastic tissues". Cold Spring Harb Symp Quant Biol. 59: 637–43. PMID 7587124.
- Maesawa C, Tamura G, Suzuki Y, Ogasawara S, Sakata K, Kashiwaba M, Satodate R (1995). "The sequential accumulation of genetic alterations characteristic of the colorectal adenoma-carcinoma sequence does not occur between gastric adenoma and adenocarcinoma". J. Pathol. 176 (3): 249–58. doi:10.1002/path.1711760307. PMID 7674088.
- Hedrick L, Cho KR, Fearon ER, Wu TC, Kinzler KW, Vogelstein B (1994). "The DCC gene product in cellular differentiation and colorectal tumorigenesis". Genes Dev. 8 (10): 1174–83. doi:10.1101/gad.8.10.1174. PMID 7926722.
- Reale MA, Hu G, Zafar AI, Getzenberg RH, Levine SM, Fearon ER (1994). "Expression and alternative splicing of the deleted in colorectal cancer (DCC) gene in normal and malignant tissues". Cancer Res. 54 (16): 4493–501. PMID 8044801.
- Suzuki T, Ishioka C, Gamo M, Niitani T, Shimodaira H, Kanbe M, Yamazaki T, Yusa Y, Kanamaru R (1994). "[Genetic alterations of human colorectal cancer]". Gan to Kagaku Ryoho. 21 (3): 343–50. PMID 8109990.
- Miyake S, Nagai K, Yoshino K, Oto M, Endo M, Yuasa Y (1994). "Point mutations and allelic deletion of tumor suppressor gene DCC in human esophageal squamous cell carcinomas and their relation to metastasis". Cancer Res. 54 (11): 3007–10. PMID 8187090.
- Cho KR, Oliner JD, Simons JW, Hedrick L, Fearon ER, Preisinger AC, Hedge P, Silverman GA, Vogelstein B (1994). "The DCC gene: structural analysis and mutations in colorectal carcinomas". Genomics. 19 (3): 525–31. doi:10.1006/geno.1994.1102. PMID 8188295.
- Keino-Masu K, Masu M, Hinck L, Leonardo ED, Chan SS, Culotti JG, Tessier-Lavigne M (1996). "Deleted in Colorectal Cancer (DCC) encodes a netrin receptor". Cell. 87 (2): 175–85. doi:10.1016/S0092-8674(00)81336-7. PMID 8861902.
- Hu G, Zhang S, Vidal M, Baer JL, Xu T, Fearon ER (1997). "Mammalian homologs of seven in absentia regulate DCC via the ubiquitin-proteasome pathway". Genes Dev. 11 (20): 2701–14. doi:10.1101/gad.11.20.2701. PMC . PMID 9334332.
- Mehlen P, Rabizadeh S, Snipas SJ, Assa-Munt N, Salvesen GS, Bredesen DE (1998). "The DCC gene product induces apoptosis by a mechanism requiring receptor proteolysis". Nature. 395 (6704): 801–4. doi:10.1038/27441. PMID 9796814.
- Hu G, Fearon ER (1999). "Siah-1 N-terminal RING domain is required for proteolysis function, and C-terminal sequences regulate oligomerization and binding to target proteins". Mol. Cell. Biol. 19 (1): 724–32. PMC . PMID 9858595.
- Meyerhardt JA, Caca K, Eckstrand BC, Hu G, Lengauer C, Banavali S, Look AT, Fearon ER (1999). "Netrin-1: interaction with deleted in colorectal cancer (DCC) and alterations in brain tumors and neuroblastomas". Cell Growth Differ. 10 (1): 35–42. PMID 9950216.
- Hilgers W, Song JJ, Haye M, Hruban RR, Kern SE, Fearon ER (2000). "Homozygous deletions inactivate DCC, but not MADH4/DPC4/SMAD4, in a subset of pancreatic and biliary cancers". Genes Chromosomes Cancer. 27 (4): 353–7. doi:10.1002/(SICI)1098-2264(200004)27:4<353::AID-GCC3>3.0.CO;2-5. PMID 10719364.
- Corset V, Nguyen-Ba-Charvet KT, Forcet C, Moyse E, Chédotal A, Mehlen P (2000). "Netrin-1-mediated axon outgrowth and cAMP production requires interaction with adenosine A2b receptor". Nature. 407 (6805): 747–50. doi:10.1038/35037600. PMID 11048721.
- Forcet C, Ye X, Granger L, Corset V, Shin H, Bredesen DE, Mehlen P (2001). "The dependence receptor DCC (deleted in colorectal cancer) defines an alternative mechanism for caspase activation". Proc Natl Acad Sci USA. 98 (6): 3416–21. doi:10.1073/pnas.051378298. PMC . PMID 11248093.